U.S. stock index futures moved higher on Monday as traders returned from a long holiday weekend, with technology-related contracts helping to lift the premarket tone. At 07:47 ET, futures tied to the Dow were little changed, S&P 500 futures had advanced by 32 points, or about 0.3%, and Nasdaq 100 futures were up roughly 289 points, or 1.1%.
Several individual names stood out before the opening bell as investors parsed company-specific developments including funding announcements, analyst coverage, and upcoming regulatory decisions. Healthcare, cryptocurrency-exposed, and energy-related shares were among the most active in the premarket session.
Here are some of the more notable premarket U.S. stock movers:
- Scilex Holding - The shares climbed about 7% after the company disclosed a binding term sheet for a proposed $100 million strategic investment from Kazakhstan-based private investment group iHolding Group LLP.
- Vera Therapeutics - The stock rose roughly 6% ahead of a July 7 Prescription Drug User Fee Act (PDUFA) decision on atacicept, the company’s investigational therapy for IgA nephropathy. Investors are awaiting the FDA’s ruling on the company’s application for accelerated approval.
- Solaris Energy Infrastructure - Shares increased near 3.9% following Wolfe Research’s initiation of coverage with an Outperform rating and a $120 price target. The company also said it had agreed to acquire power generation services provider Global Energy Services Alliance for about $55 million in cash and stock.
- Strategy - The stock jumped about 3.4% after investors continued to digest the company’s newly adopted Digital Credit Capital Framework. The framework authorizes selective monetization of up to $1.25 billion of its Bitcoin holdings to bolster liquidity, fund preferred dividends and support share repurchases.
Market participants cited a mix of corporate financing moves, analyst actions, and an approaching regulatory decision as the primary drivers of premarket activity. The overall advance in futures suggests a modestly risk-on posture among traders returning from the holiday break, with technology contracts notably stronger than the blue-chip futures at the same snapshot in time.
Given the clustered nature of the headlines - ranging from investment commitments to an upcoming FDA review and an analyst initiation - premarket volumes may reflect targeted responses to specific catalysts rather than broad-based sector rotations.
Investors and market observers will be watching the scheduled regulatory timeline and integration details on announced transactions for further guidance on near-term share performance across these names.